News
CRBU
3.760
-2.34%
-0.090
Caribou Biosciences To Present Initial Dose Expansion Data From CB-010 ANTLER Phase 1 Trial In r/r B-NHL At The 2024 American Society Of Clinical Oncology Annual Meeting
Caribou Biosciences, Inc. Announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology Annual Meeting. Caribou is a leading clinical-stage CRISPR genome-editing company. The company's CAR-T cell therapy candidate, CB-010, is being tested in patients with relapsed/refractory B cell lymphoma.
Benzinga · 1d ago
Weekly Report: what happened at CRBU last week (0415-0419)?
Weekly Report · 3d ago
Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
Seeking Alpha · 04/18 17:59
More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%
Caribou Biosciences, Inc. Has seen a 25% share price drop in the last month. The company's price-to-sales ratio is 10.5x compared to the industry median P/S of 13x. Its revenue growth is forecast to decline over the next three years. We believe the company's P/s is too high for a company with a poor revenue growth outlook. Caribou B biosciences has been growing revenue less than most other companies lately.
Simply Wall St · 04/17 10:14
Caribou Biosciences Announces Oral Presentation On In Vivo Cas12a chRDNA Genome Editing At The 27th Annual Meeting Of ASGCT
Caribou Biosciences, Inc. Is a leading clinical-stage CRISPR genome-editing company. The company has accepted an abstract for an oral presentation at the American Society of Gene and Cell Therapy in May 2024. The abstract is on the efficient use of Cas12a chRDNA for in vivo hepatic gene disruption.
Benzinga · 04/15 13:15
CARIBOU BIOSCIENCES ANNOUNCES ORAL PRESENTATION ON IN VIVO CAS12A CHRDNA GENOME EDITING AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT)
Reuters · 04/15 13:00
Weekly Report: what happened at CRBU last week (0408-0412)?
Weekly Report · 04/15 09:13
Weekly Report: what happened at CRBU last week (0401-0405)?
Weekly Report · 04/08 09:14
Buy Rating Affirmed: Caribou Biosciences’ Promising Trials and Strategic Market Positioning
TipRanks · 04/08 07:25
Analysts Offer Insights on Healthcare Companies: Caribou Biosciences (CRBU), Icon (ICLR) and Teladoc (TDOC)
TipRanks · 04/05 12:41
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Shares of Kura Sushi USA, Inc. Climbed 6% to $110.11 in pre-market trading following the release of second-quarter results. DigiAsia Corp. Shares climbed 61.8% after falling 18% on Thursday. Invivyd shares climbed 10.9% after the company issued a launch update.
Benzinga · 04/05 12:01
Institutional investors may adopt severe steps after Caribou Biosciences, Inc.'s (NASDAQ:CRBU) latest 12% drop adds to a year losses
Institutional investors own 64% of Caribou Biosciences, Inc. (NASDAQ:CRBU) The company has a market value of US$423m. The top 10% of the company's shares are held by the top 10 shareholders. The company is owned by institutions and hedge funds. This indicates the company has significant influence over the share price of the stock.  Caribou Bio's biggest shareholders saw their stake in the company drop by 12% last week. We look at the company and its ownership of shares. Caribou bioscience has a large amount of shares in the market.
Simply Wall St · 04/05 10:00
Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)
TipRanks · 04/05 09:40
Analysts Are Bullish on Top Healthcare Stocks: Paragon 28 (FNA), Caribou Biosciences (CRBU)
TipRanks · 04/05 09:00
Caribou Biosciences Advances with FDA Clearance and New Trials
TipRanks · 04/04 20:24
Caribou Biosciences received IND clearance from FDA for its lupus treatment
Healthcare Caribou Biosciences received IND clearance from FDA for its lupus treatment. The Phase 1, multicenter, open label clinical trial of CB-010 is expected to initiate by year-end 2024. Caribou continues to expect the $372.4 million cash to fund the current operating plan.
Seeking Alpha · 04/04 20:07
CARIBOU BIOSCIENCES INC - $372.4 MLN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES, AS OF DEC 31, 2023, TO FUND CURRENT OPERATING PLAN INTO Q1 2026
Reuters · 04/04 20:00
CARIBOU BIOSCIENCES EXPANDS CLINICAL DEVELOPMENT OF CB-010 WITH FDA CLEARANCE OF IND IN LUPUS
Reuters · 04/04 20:00
Biotech Roundtable: Who will bring the next CRISPR drug to market?
Healthcare Biotech Roundtable: Who will bring the next CRISPR drug to market? CRisPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. Last fall, the FDA approved the first CRISpr product for the US market. Seeking Alpha asked three analysts to weigh in on the technology and companies working in it.
Seeking Alpha · 04/02 15:36
More
Webull provides a variety of real-time CRBU stock news. You can receive the latest news about Caribou Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.